Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Amycretin

INVESTIGATIONAL

Unimolecular GLP-1 and amylin receptor agonist

5
graded results
0
ongoing records
4
effect domains
Evidence spread
High evidence 0Moderate evidence 3Low evidence 2Very low evidence 0

Amycretin is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Type 2 diabetes and obesity; Oral and subcutaneous formulations; as of 2026-07-13. Novo Nordisk

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin INVESTIGATIONAL
weight-loss Decrease
Moderate evidence

Oral amycretin: first-in-human pharmacodynamic weight reduction over 12 wk

Gasiorek A et al. Lancet 2025;406:135-148 Source
PopulationOverweight/obese (BMI 25-39.9), phase 1 first-in-human (n=144), single + multiple ascending oral doses (NCT05369390)
Fundingindustry - Novo Nordisk
Comparatorsplacebo
Amycretin INVESTIGATIONAL
weight-loss Decrease
Low evidence

Subcutaneous amycretin produced large dose-dependent weight loss over 20-36 wk

Dahl K, Toubro S et al. Amycretin, unimolecular GLP-1 and amylin receptor agonist s.c.: p... Source
PopulationOverweight/obese (BMI 27-39.9), phase 1b/2a (n=125; 101 amycretin), up to 36 wk, RCT placebo-controlled (NCT06064006)
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin INVESTIGATIONAL
glycaemic Decrease
Moderate evidence

Fasting plasma glucose change assessed as exploratory PD endpoint (oral)

Gasiorek A et al. Lancet 2025;406:135-148 Source
PopulationPhase 1 oral first-in-human (n=144)
Fundingindustry - Novo Nordisk
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin INVESTIGATIONAL
pharmacology Not directional
Moderate evidence

First-in-class single-molecule GLP-1R + amylin receptor agonist; both oral and s.c. formulations; dose-proportional exposure

Gasiorek A et al. Lancet 2025;406:135-148 Source
PopulationPhase 1 oral and phase 1b/2a s.c.
Fundingindustry - Novo Nordisk
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin INVESTIGATIONAL
Stomach and gut Increase
Low evidence

Predominantly GI TEAEs, mild-to-moderate, dose-dependent; all resolved

Dahl K, Toubro S et al. Amycretin, unimolecular GLP-1 and amylin receptor agonist s.c.: p... Source
Populations.c. phase 1b/2a (n=125) and oral phase 1 (n=144)
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Comparatorsplacebo